|
|
Kosan Biosciences News (NASDAQ:KOSN)
| Latest Kosan Biosciences News Headlines | | Date | Time | Source | | | 06/03/2008 | 9:00AM | PRNUS | Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breas
Data Presented at ASCO Show 26% Partial Response, 63% Clinical Benefit Incidence
HAYWARD, Calif., June 3 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) today announced that its lead Hsp90 inhibitor, tanespimycin, demonstrated a high level of antitumor activity in a Phase 2 trial when administered... More...>> |
| 05/20/2008 | 6:00AM | PRNUS | Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
HAYWARD, Calif., May 20 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) today announced the appointment of Pamela S. Cohen, M.D., as Senior Vice President and Chief Medical Officer. Dr. Cohen is a recognized expert in the global development and registration of cancer therapeutics and has had a... More...>> |
| 05/14/2008 | 6:00AM | PRNUS | Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
HAYWARD, Calif., May 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) today announced that updated data will be presented on tanespimycin, the company's lead Hsp90 inhibitor, from a Phase 2 trial in combination with Herceptin(R) in patients with HER2-positive metastatic breast cancer, at the... More...>> |
| 05/06/2008 | 4:00PM | PRNUS | Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
HAYWARD, Calif., May 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) announced today that Jane Green, Kosan's Vice President, Corporate Communications, will present at the Leerink Swann Solid Tumors Roundtable Conference in New York at the Grand Hyatt Hotel on Friday, May 9, 2008 at 11:10 a.m... More...>> |
| 05/01/2008 | 4:00PM | PRNUS | Kosan Announces First Quarter 2008 Financial Results
HAYWARD, Calif., May 1 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) today reported financial results for the quarter ended March 31, 2008.
Net loss for the quarter ended March 31, 2008 was $8.5 million, or $0.20 per share, compared to net income of $2.7 million, or $0.07 per share, in the... More...>> |
| 04/25/2008 | 6:00AM | PRNUS | Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
HAYWARD, Calif., April 25 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) will announce its first quarter 2008 financial results on Thursday, May 1, 2008, after market close.
The announcement of Kosan's first quarter 2008 financial results will be followed by a conference call and live webcast... More...>> |
| 04/16/2008 | 4:09PM | PRNUS | Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
HAYWARD, Calif., April 16 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) presented data on its novel, proprietary third-generation Hsp90 inhibitors demonstrating a high degree of target specificity, strong binding affinity and potency, a long lifetime in tumor tissue and significant antitumor... More...>> |
| 04/16/2008 | 4:06PM | PRNUS | Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
HAYWARD, Calif., April 16 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) presented preclinical data on its proprietary nuclear export inhibitors (NEI) showing potent in vitro and in vivo activity as well as tolerability in leukemia xenograft models, and further elucidating the NEI anticancer... More...>> |
| 04/14/2008 | 6:00AM | PRNUS | Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
HAYWARD, Calif., April 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) today announced that the Phase 2 trial of epothilone KOS-1584 in patients with non-small cell lung cancer has been initiated. The Phase 2 trial is an open-label, multi-center, monotherapy study of KOS-1584 in patients with... More...>> |
| 03/18/2008 | 6:45PM | PRNUS | Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
HAYWARD, Calif., March 18 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) today announced that the company will reduce its workforce by approximately 37% in order to focus resources on supporting advancement of its lead clinical programs, tanespimycin in multiple myeloma and in metastatic breast... More...>> |
| 03/18/2008 | 4:00PM | PRNUS | Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer
HAYWARD, Calif., March 18 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) today announced that its Board of Directors has appointed Helen S. Kim as Chief Executive Officer, effectively immediately. Ms. Kim joined Kosan in January 2008 as Senior Vice President and Chief Business Officer, and was... More...>> |
| 03/14/2008 | 6:00AM | PRNUS | Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
HAYWARD, Calif., March 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) announced today that Gary S. Titus, Kosan's Senior Vice President and Chief Financial Officer, will present at the Cowen and Company 28th Annual Health Care Conference in Boston at the Boston Marriott Copley Place on Wednesday... More...>> |
| 02/29/2008 | 6:00AM | PRNUS | Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
HAYWARD, Calif., Feb. 29 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) announced today that Gary S. Titus, Kosan's Senior Vice President and Chief Financial Officer, will present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference in New York at the W Hotel on Tuesday... More...>> |
| 02/28/2008 | 4:05PM | PRNUS | Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
HAYWARD, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) today reported financial results for the quarter and year ended December 31, 2007.
Net losses for the quarter and year ended December 31, 2007 were $9.5 million and $28.7 million, or $0.22 and $0.69 per share, compared to... More...>> |
| 02/28/2008 | 4:00PM | PRNUS | Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
Robert G. Johnson, Jr. Resigns as President and Chief Executive Officer
HAYWARD, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) today announced that Robert G. Johnson, Jr., M.D., Ph.D., has resigned as President and Chief Executive Officer and a member of Kosan's Board of Directors... More...>> |
| 02/07/2008 | 4:00PM | PRNUS | Kosan Announces February 28, 2008 Conference Call and Webcast
FOURTH QUARTER AND FULL YEAR 2007 FINANCIAL RESULTS, 2008 OUTLOOK AND UPDATE ON KOSAN'S PLANS TO BE DISCUSSED ON CONFERENCE CALL AND WEBCAST
HAYWARD, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) will discuss its fourth quarter and full year 2007 financial results, 2008 financial... More...>> |
| 01/15/2008 | 6:00AM | PRNUS | Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
HAYWARD, Calif., Jan. 15 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) today announced the initiation of a Phase 2 trial of alvespimycin, the company's second-generation Hsp90 inhibitor, in patients with HER2-positive metastatic breast cancer. Alvespimycin has demonstrated the potential to disrupt... More...>> |
| 01/03/2008 | 4:00PM | PRNUS | Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
Kosan Leads Industry with Most Advanced Hsp90 Inhibitor in Clinical Development
HAYWARD, Calif., Jan. 3 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) today announced that the Tanespimycin in Myeloma Evaluation or TIME-1 pivotal Phase 3 trial for tanespimycin as a potential treatment for multiple... More...>> |
| 01/03/2008 | 6:00AM | PRNUS | Kosan Appoints Helen S. Kim as Chief Business Officer
HAYWARD, Calif., Jan. 3 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) today announced the appointment of Helen S. Kim as Senior Vice President and Chief Business Officer, responsible for the company's business and corporate development strategies, including corporate partnering and licensing... More...>> |
| 12/17/2007 | 6:00AM | PRNUS | Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Canc
Five of 20 Evaluable Patients Had Confirmed Partial Responses (25%); Updated Data Presented at San Antonio Breast Cancer Symposium
HAYWARD, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NASDAQ:KOSN) today announced that its Hsp90 inhibitor, tanespimycin, demonstrated meaningful antitumor... More...>> |
|
|
|